In 2025, the Phase 1 Unit initiated 12 new early phase studies hereof 7 first-in-human studies for solid tumor indications and multiple trials for hematological malignancies underscoring our ongoing commitment to bringing innovative therapies into early clinical development and improving access to experimental treatments for patients. An overview of ongoing trials is available at Clinical Trials on Rigshospitalet. These studies span a broad range of compounds, from small molecules, protein degraders, bi-specific T-cell engagers to antibody-drug conjugates and contribute to strengthening Denmark's position in Phase 1 research both nationally and internationally.
Click here for overview of ongoing trials
National and International Collaboration
A significant highlight of the year has been our active participation in European collaborative initiatives in precision cancer medicine, including PCM4EU, PRIME-ROSE, eCAN+, and JA PCM. Through these EU projects, the Phase 1 Unit has contributed to the development of frameworks that support personalised cancer medicine, shape how molecular profiling, targeted therapies, and innovative trial designs are integrated into clinical trials across Europe.
National collaboration has continued to play a central role in 2025. Close cooperation with hospitals, research institutions, and clinical networks across Denmark has supported efficient study implementation and knowledge exchange. Our ongoing collaboration with ProTarget and participation in the National Molecular Tumor Board remain key elements in our efforts to accelerate patient access to targeted treatments based on molecular characteristics, reinforcing the nationwide implementation of precision oncology in clinical practice.
Thank You
The achievements of 2025 would not have been possible without the dedicated efforts of our internal collaborators at Rigshospitalet, including clinical staff, research teams, laboratories, and administrative support, as well as our valued external partners in academia, industry, and collaborative networks. Your engagement and professionalism are essential to the success of our work. A special thank you to all patients and their families.
As we look ahead to the coming year, we do so with appreciation for the progress made and optimism for future opportunities. We extend our sincere thanks to everyone who has contributed to the Phase 1 Unit's activities in 2025 and wish you all a happy New Year.